
Epigenetics

Current and future applications that are
driving novel drug discovery

August 2010



World Leaders in Health Industry Analysis



Epigenetics: Current and future applications that are driving novel drug discovery

August 2010

ISBN: 978 1 85822 394 0

© Copyright 2010 Espicom Business Intelligence

All rights reserved. No part of this publication may be reproduced or used in any form or by any means graphic, electronic or mechanical, including photocopying, recording, taping or storage in information retrieval systems without the express permission of the publisher.

Every care has been taken to ensure that the information contained in this report is correct. The publisher accepts no liability for decisions made on the basis of information contained herein.

British Library Cataloguing in Publication Data.

A catalogue record for this report is available from the British Library.

Contents

The Business Implications	1
Chapter 1 - Epigenetics Defined	3
Executive Summary.....	4
Epigenetics defined	4
EPIGENETICS DEFINED	5
Epigenetic mechanisms.....	6
DNA methylation	6
<i>Figure 1: Schematic showing the epigenetic mechanisms of DNA methylation and histone modification</i>	6
Chromatin remodelling and histone modifications	7
<i>Figure 2: Examples of covalent histone post-translational modifications</i>	7
Non-coding RNA	8
<i>Figure 3: miRNA processing pathway</i>	8
Unravelling the power of epigenetics	9
EXPERT COMMENTARY: Professor Stephan Beck, University College London Cancer Institute	10
Consortia for the study of epigenomics.....	10
Which epigenomes and what to study?	10
Applications of epigenomic data.....	10
New opportunities for biomarker discovery and drug targeting	11
Conclusion and report outline	11
Chapter 2 - Technical Challenges in Epigenetic R&D	13
Executive Summary.....	14
Technical challenges in epigenetic R&D	14
TECHNICAL CHALLENGES IN EPIGENETIC R&D	15
EXPERT COMMENTARY: Dr Chris Adams, Senior R&D Manager/Epigenetics, Life Technologies	15
Next generation sequencing	16
<i>Table 1: Platforms for next generation sequencing</i>	16
<i>Table 2: Third generation sequencing platforms</i>	17
DNA methylation	17
<i>Table 3: Methods for studying DNA methylation and their limitations</i>	17
<i>Table 4: Suppliers of research tools for the study of DNA methylation</i>	18
Chromatin structure and histone modifications	19
<i>Figure 4: Schematic of a chromatin immunoprecipitation experiment</i>	19
<i>Table 5: Suppliers of research tools for the study of histone and chromatin modifications</i>	20
microRNA	20
<i>Table 6: Suppliers of research tools for the study of miRNA</i>	21
Conclusion	21
Chapter 3 - Epigenetics in Drug Discovery & Development	23
Executive Summary.....	24
Epigenetics in drug discovery & development	24
EPIGENETICS IN DRUG DISCOVERY & DEVELOPMENT	25
Introduction.....	25
<i>Figure 5: Proteins involved in the modification of histones</i>	25
<i>Figure 6: Number of drugs targeting epigenetic mechanisms by mechanism and stage of development</i>	26
Epigenetics in cancer	26
Epigenetic drug targets in cancer: DNA methyltransferases	27
<i>Table 7: Approved drugs targeting DNMTs</i>	27
Epigenetic drug targets in cancer: HDAC inhibitors	28
Non-selective HDAC inhibitors	28

<i>Table 8: Pan-HDAC inhibitors in clinical development</i>	28
EXPERT COMMENTARY: Dr Bernd Hentsch, Chief Development Officer, 4SC AG	29
Selective HDAC inhibitors	30
<i>Table 9: Selective HDAC inhibitors</i>	30
EXPERT COMMENTARY: Dr David Simmons (CSO) & Dr Gitte Neubauer (VP Research Operations), Cellzome	31
Beyond DNMT and HDAC inhibition: New targets	32
<i>Table 10: Companies developing drugs for novel epigenetic targets</i>	33
EXPERT COMMENTARY: Dr Robert Gould, CEO, Epizyme Inc	33
EXPERT COMMENTARY: Martin Bonde, CEO, EpiTherapeutics	34
Cancer the first frontier, where next?	35
<i>Table 11: Companies developing therapeutics for epigenetic mechanisms in diseases other than cancer</i>	35
Non-coding RNAs	35
<i>Table 12: Companies developing therapeutic strategies related to miRNAs</i>	35
<i>Table 13: Therapeutic areas for miRNA-based therapeutic discovery</i>	36
EXPERT COMMENTARY: Dr. Andreas G. Bader, Associate Director of Research, Mirna Therapeutics, Inc.	37
The future	38
Chapter 4 - Epigenetics in Clinical Diagnostics	39
Executive Summary	40
Epigenetics in clinical diagnostics	40
EPIGENETICS IN CLINICAL DIAGNOSTICS	41
Introduction	41
DNA methylation patterns	41
<i>Table 14: Companies developing diagnostics to detect aberrant DNA methylation patterns</i>	41
Epigenomics AG	42
<i>Figure 7: Epigenomics' development programme</i>	42
OncoMethylome Sciences	43
<i>Figure 8: OncoMethylome Sciences' development programme</i>	43
Orion Genomics	44
<i>Figure 9: Orion Genomics' product development pipeline</i>	44
Histone modifications	45
miRNAs	45
Rosetta Genomics	45
<i>Table 15: Approved and developmental diagnostic products from Rosetta Genomics</i>	45
Asuragen Diagnostics	46
Exiqon A/S	46
<i>Table 16: Exiqon's miRNA-based diagnostic pipeline</i>	47
Biomarkers and personalised medicine	47
<i>Table 17: Diagnostic/pharma partnerships for epigenetic biomarker discovery</i>	47
Outlook	48
Chapter 5 - Players, Alliances & Acquisitions	49
Executive Summary	50
Players, alliances & acquisitions	50
PLAYERS, ALLIANCES & ACQUISITIONS	51
Company activities at a glance – Therapeutics	51
<i>Table 18: Areas of focus for companies developing drugs for epigenetic targets</i>	51
4SC AG, Planegg-Martinsried, Germany	52
Acetylon Pharmaceuticals Inc, Boston, MA	52
Celgene Corporation, Summit, NJ	52
Celleron Therapeutics, Oxon, UK	52
Cellzome, Cambridge, UK, and Heidelberg, Germany	53
Curis Inc, Cambridge MA	53

Chroma Therapeutics Ltd, Oxon, UK53
Constellation Pharmaceuticals, Cambridge, MA54
EnVivo Pharmaceuticals, Watertown, MA.....54
EpiTherapeutics Aps, Copenhagen, Denmark54
Epizyme, Cambridge, MA54
MethylGene, Inc. Montreal, Québec55
Mirna Therapeutics, Austin, TX.....55
miRagen Therapeutics, Boulder, CO.....55
Pharmacyclics, Sunnyvale, CA55
Progen Pharmaceuticals, Brisbane, Australia56
Regulus Therapeutics, Torrey Pines, CA56
Repligen Corporation, Waltham, MA56
Santaris Pharma A/S, Denmark.....56
SuperGen, Dublin, CA56
Syndax Pharmaceuticals, Waltham, MA57
TopoTarget, Copenhagen, Denmark57
Alliances with market leaders – Therapeutics 58
Table 19: Alliances, acquisitions and mergers in the field of epigenetics since 2007 59
Table 20: Areas of focus for companies developing diagnostic tests based on epigenetics 60
Asuragen Inc, Austin, TX60
Epigenomics AG, Berlin, Germany60
Exiqon, Copenhagen, Denmark60
OncoMethylome Sciences, Durham, NC.....61
Orion Genomics, Saint Louis, MO61
Rosetta Genomics, Rehovot, Israel61
Alliances with market leaders – Diagnostics61
Conclusion.....62

Chapter 6 - Outlook & Future of Epigenetic Research 63
Executive Summary..... 64

OUTLOOK & FUTURE OF EPIGENETIC RESEARCH 65
Epigenetics research now 65
Figure 10: Progress in epigenetics related therapeutics and diagnostics over the next 5 years 65
Therapeutic launches and new indications over the next 5 years66
Table 21: Revenues generated by Vidaza, Dacogen and Zolinza in 2009..... 66
New combinations and a changing therapeutic paradigm in cancer67
Table 22: Examples of clinical trials of combinations of DNMTi, HDACi and chemotherapy..... 67
Table 23: Examples of clinical trials of drug combinations including panobinostat 68
New diagnostic products.....69
Table 24: New diagnostic products identifying epigenetic biomarkers that will be launched to the market over the next few years 69
Next generation sequencing.....69
Epigenetics research in 5 to 10 years time70
Figure 11: Progress in epigenetics related therapeutics and diagnostics over the next 5 to 10 years..... 70
Therapeutic launches.....70
Therapeutics and companion diagnostics for novel epigenetic targets71
Epigenetics research more than 10 years from now 72
Figure 12: Progress in epigenetics-related therapeutics and diagnostics 10 years + 72
Conclusions 73

GLOSSARY 74
BIOGRAPHY OF THE AUTHOR 75
REFERENCES 76
ENDNOTES 79